<DOC>
	<DOCNO>NCT02758951</DOCNO>
	<brief_summary>The purpose study determine whether cytoreductive surgery HIPEC , combine preoperative chemotherapy target therapy postoperative chemotherapy , result improve overall survival compare cytoreductive surgery HIPEC alone patient peritoneal metastasis colorectal cancer . A survival increase 15 % expect systemic therapy group . Furthermore , neoadjuvant systemic therapy may allow good patient selection .</brief_summary>
	<brief_title>Perioperative Systemic Therapy Patients Undergoing Surgery With HIPEC Colon Cancer With Peritoneal Metastases : CAIRO6 Study .</brief_title>
	<detailed_description>Rationale : Both cytoreductive surgery hyperthermic intraperitoneal chemotherapy ( CRS + HIPEC ) systemic therapy increasingly use treatment peritoneal metastases colorectal cancer ( PMCRC ) . Subsequently , combine treatment strategy introduce . However , worldwide controversy indication , effectiveness , timing , risk perioperative systemic therapy adjunct CRS + HIPEC PMCRC . Although study describe use perioperative systemic therapy neoadjuvant adjuvant setting , neither strategy ever prospectively investigated patient undergo CRS + HIPEC PMCRC . Current literature perioperative systemic therapy adjunct CRS + HIPEC base observational study low methodological quality . A neoadjuvant treatment strategy order downstage intraperitoneal tumour load , limit extensiveness CRS , predict biological behaviour tumour , may potential benefit patient . In patient proved respond neoadjuvant treatment , adjuvant systemic therapy regimen may value treat systemic micro-metastases . Objective : The primary objective study determine potential survival benefit perioperative treatment strategy consist neoadjuvant adjuvant combination chemotherapy neoadjuvant bevacizumab patient undergo CRS + HIPEC PMCRC . Study design : This prospective multicentre randomise , parallel group study eligible patient randomise neoadjuvant combination chemotherapy plus bevacizumab CRS + HIPEC follow adjuvant combination chemotherapy ( experimental arm ) , CRS + HIPEC alone ( control arm ) . The study start randomise phase II study investigate feasibility strategy term accrual ass safety neoadjuvant combination chemotherapy/bevacizumab prior CRS + HIPEC . If criteria feasibility safety meet , study continue phase III study 3-year overall survival primary endpoint . Study population : Patients non-signet cell synchronous metachronous PMCRC , without systemic metastasis site , candidate CRS + HIPEC ( PCI score ≤20 ) , ( nearly ) complete cytoreduction ( CC-0 CC-1 ) seem feasible . Intervention : Patients experimental arm receive neoadjuvant combination chemotherapy plus bevacizumab three 3-weekly ( CAPOX + BEV ) four 2-weekly ( FOLFOX + BEV ) cycle , follow restaging thoraco-abdominal CT-scan . In case progressive unresectable disease , best possible palliative treatment offer . In case progressive resectable disease , patient undergo explorative laparotomy subsequent CRS + HIPEC least 6 week last cycle bevacizumab administer . In case responsive stable disease , one 3-weekly ( CAPOX ) two 2-weekly ( FOLFOX ) neoadjuvant cycle combination chemotherapy without bevacizumab administer . Subsequently , early 3 week last day last cycle combination chemotherapy , explorative laparotomy subsequent CRS + HIPEC perform . Only patient stable disease response upon neoadjuvant treatment , adjuvant combination chemotherapy give accord neoadjuvant regimen , without bevacizumab , four 3-weekly cycle ( CAPOX ) six 2-weekly cycle ( FOLFOX ) . Study parameter : Regarding feasibility safety , endpoint phase II study number randomise patient 1 year start accrual participating centre , major postoperative complication ( Clavien-Dindo grade III-V ) 3 month postoperatively , number patient receive CRS + HIPEC . Secondary endpoint minor postoperative complication ( Clavien-Dindo grade II ) systemic therapy relate toxicity ( NCICTCAE v4.0 Grade II-V ) . The phase II study deem unfeasible &lt; 80 patient randomise , deem unsafe : - There 7 patient difference major postoperative complication disadvantage experimental arm compare control arm . - le 50 % ( 20/40 ) include patient experimental arm able proceed CRS + HIPEC . The primary endpoint phase III study 3-year overall survival . Secondary endpoint 5-year overall survival , 3 5-year disease free survival , procedure relate characteristic ( i.e . operative time , blood loss ) , peritoneal cancer index ( PCI ) score , completeness cytoreduction ( CC ) score , major postoperative complication ( Clavien-Dindo grade III-V ) 90-days postoperatively , hospital stay , quality life , cost-effectiveness . In experimental arm , additional secondary endpoint severe systemic therapy-related toxicity ( NCICTCAE v4.0 grade III-V ) , number patient progression , stable disease , response neoadjuvant combination chemotherapy plus bevacizumab . Sample size : The phase II study include 80 patient , 40 patient arm . After fulfil criterion feasibility randomisation safety neoadjuvant combination chemotherapy plus bevacizumab , study continue phase III superiority study 3 year overall survival primary endpoint . The expected 3-year overall survival CRS + HIPEC 50 % . We hypothesize experimental treatment result 15 % increase overall survival rate analyse accord intention-to-treat principle . With 0.05 two-sided significance level , 80 % power drop-out 5 % , sample size 170 patient arm need , result total 340 patient , include 80 patient phase II study . Time schedule : In 2016 , expect number patient refer CRS + HIPEC PMCRC Netherlands 250 . With expect participation rate 40 % , accrual complete 4 year . Nature extent burden risk : In experimental arm , risk study primarily consist treatment-related toxicity morbidity combination chemotherapy bevacizumab , weigh potential survival benefit . Furthermore , patient experimental arm may disease progression upon neoadjuvant treatment extent allow CRS + HIPEC . However , highly questionable whether patient would derive benefit upfront CRS + HIPEC , investigator hypothesise neoadjuvant treatment strategy allow well patient selection spare morbidity intervention patient unlikely benefit .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Peritoneal Diseases</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Inclusion criterion : PCI score ≤20 CC0 CC1 achievable , determined adequate preoperative workup . Pathological confirmation colorectal cancer nonsignet histology peritoneal deposit ascites . 18 year old . WHO performance score 01 . Adequate clinical condition undergo CRS + HIPEC neoadjuvant combination chemotherapy bevacizumab within 4 week randomisation . Adequate organ function : normal bone marrow function ( Hb ≥6.0 mmol/L , absolute neutrophil count ≥1.5 x 109/L , platelet count ≥100 x 109/L ) , renal function ( serum creatinine ≤1.5 x ULN creatinine clearance [ Cockroft formula ] ≥30 ml/min ) , determine &lt; 3 month prior randomisation . No known bleeding diathesis coagulopathy . Written informed consent . Able willing adhere followup . Exclusion criterion : Signet ring cell histology ( &gt; 50 % cell signet ring cell histology ) primary tumour . Systemic metastasis ( i.e . liver , lung ) Known pregnancy lactation . Known unstable uncompensated respiratory cardiac disease . Serious active infection . Adjuvant chemotherapy primary resection colorectal cancer use within 6 month prior randomisation . Any condition allow safe administration plan systemic treatment ( bevacizumab , 5fluorouracil , leucovorin , capecitabine , oxaliplatin , irinotecan ) . Stomatitis , ulceration mouth gastrointestinal tract . Severe diarrhoea . Known pernicious anaemia anaemia due vitamin B12 deficiency . Known previous peripheral sensory neuropathy functional impairment previous use oxaliplatin . Impaired liver function ( serum bilirubin ≤2 x ULN , serum transaminase ≤5 x ULN ) , assessment indicate . Known dihydropyrimidine dehydrogenase deficiency , determine dihydropyrimidine dehydrogenase genotyping .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Induction Chemotherapy</keyword>
	<keyword>Chemotherapy , Adjuvant</keyword>
	<keyword>Molecular Targeted Therapy</keyword>
	<keyword>Colorectal Surgery</keyword>
	<keyword>Cytoreductive Surgery</keyword>
	<keyword>Hyperthermic Intraperitoneal Chemotherapy</keyword>
	<keyword>Peritoneum</keyword>
	<keyword>Peritoneal Lavage</keyword>
	<keyword>Peritoneal Cavity</keyword>
	<keyword>Ascitic Fluid</keyword>
	<keyword>Chemotherapy , Cancer , Regional Perfusion</keyword>
	<keyword>Antineoplastic Combined Chemotherapy Protocols</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Morbidity</keyword>
	<keyword>Mortality</keyword>
	<keyword>Hospital Mortality</keyword>
	<keyword>Chemically-Induced Disorders</keyword>
	<keyword>Drug-Related Side Effects Adverse Reactions</keyword>
	<keyword>Laparotomy</keyword>
</DOC>